Arcutis Biotherapeutics is going long with the latest push for its seborrheic dermatitis treatment Zoryve. | Arcutis ...

The football star got real with Cosmo about his recent experience with seborrheic dermatitis and so much more.

Odell Beckham Jr. opened up about his health and a recent diagnosis. “When I found out millions of others had this condition, ...

Matsuda Masaru, Senior Vice President at Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), recently sold shares of the company's ...

Zoryve (roflumilast) is a brand-name drug that’s prescribed for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in adults and some children. Zoryve comes as a topical cream or ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful ...

In a recent transaction, Howard G. Welgus, a director at Arcutis Biotherapeutics Inc . (NASDAQ:ARQT), sold 10,000 shares of the company's common stock. The shares were sold at a weighted average price ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

Roflumilast 0.3%. Roflumilast and its active metabolite (roflumilast N-oxide) are inhibitors of phosphodiesterase 4 (PDE4). Roflumilast and roflumilast N-oxide inhibition of PDE4 (a major cyclic-3 ...

The company’s product launch of Zoryve helped to drive Q3 earnings beyond expectations and the stock price up a remarkable 360% year-to-date. The demand for the treatment in various forms has ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on January 29.Maximize Your Portfolio ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on January 13.Invest with Confidence: ...